CONTENTS

Acknowledgement c		
Abstract in Thai d		
Abstract in English f		
List of Tables j		
List of Figure	es states and states	1
List of Abbreviations n		
Chapter 1	Introduction	1
Chapter 2	Literature Review	4
	2.1 History of HIV and AIDS	4
2.2 Human Immunodeficiency Virus (HIV) 5		
2.2.1 HIV particle 5		
2.2.2 HIV genome 6		
2.2.3 HIV replication 8		
2.3 Genetic diversity of HIV 10		
2.3.1 HIV classifications102.3.2 HIV recombinants12		
2.3.3 Mechanisms of genetic diversity 13		
A	2.4 The implication of HIV epidemiology study	16
2.4.1 Transmission and disease progression 16		
2.4.2 Diagnosis and monitoring tests		
	2.4.3 Response to therapy in HIV-1 subtype	19
	2.4.4 HIV vaccine	20
	2.5 Epidemiology of HIV infection and global distribution	20

CONTENTS

Chapter 3	Materials and Methods	29	
	3.1 Study population	29	
	3.1.1 Sample collection and storage	34	
	3.1.2 Research design	34	
	3.2 Materials and methods	36	
	3.2.1 V3 serotyping by subtype-specific enzyme	36	
	immunoassay (SSEIA)	•	
	3.2.2 Determination of HIV-1 <i>gag-pol</i> genotyping	39	
	3.2.3 Evaluation of HIV-1 V3 serotype and <i>gag-pol</i>	39	
	genotyping		
	3.2.4 HIV-1 env gp120 C2-V3-C3 genotyping	39	
	3.2.5 Determination of HIV-1 env gp120 C2-V3-C3	42	
	genotyping		
	3.2.6 Phylogenetic analysis	42	
	3.2.7 Statistical analysis	43	
	AI UNIVER		
Chapter 4	Results	44	
	4.1 The results of HIV-1 V3 serotype	44	
	4.2 The results of <i>gag-pol</i> genotype	48	
	4.3 The results of evaluation of HIV-1 V3 serotype and		
A	gag-pol genotype		
	4.4 The results of HIV-1 env gp120 C2-V3-C3 genotype	55	
	4.5 The results of phylogenetic analysis	68	
Chapter 5	Chapter 5 Conclusion and Discussion		
References		83	
Curriculum Vitae		100	

LIST OF TABLES

3.1	Number of the first treatment-experienced HIV-1 infected	31
	patients who participated in the NAP by NHSO	
3.2	Number of the second population, treatment-experienced	33
	HIV-1 infected patients who participated in the NAPHA	
	EXTENSION program	
3.3	Sequences of the synthetic peptides that using in HIV-1	36
	SSEIA	
3.4	The example of locations in the microplate	38
3.5	The example of comparing results of HIV-1 V3 serotype and	39
	gag-pol genotype	
4.1	The results of HIV-1 V3 serotype in each study population	45
	that separated by year of sample collection	
4.2	The results of HIV-1 V3 serotype in the available samples of	47
	all study populations	
4.3	The details of samples that showed indeterminate serotype	47
4.4	The results of HIV-1 gag-pol genotype among the first and	49
	second study populations during 2009-2012	
4.5	The results of HIV-1 gag-pol genotype in the first and second	51
d	study populations, categorized by year of sample collection	
4.6	The results of evaluation of HIV-1 V3 serotype and gag-pol	54
A	genotype in each study population and year of sample collection	
4.7	The results of evaluation of HIV-1 V3 serotype and gag-pol	55
	genotype that classified subtype	
4.8	The results of gag-pol genotype, V3 serotype and env C2V3C3	56
	genotype in 73 discordant results	
4.9	The details of patients who infected with HIV-1 subtype C,	59
	G and inter-subtype recombinants	
	 3.2 3.3 3.4 3.5 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 	 patients who participated in the NAP by NHSO 3.2 Number of the second population, treatment-experienced HIV-1 infected patients who participated in the NAPHA EXTENSION program 3.3 Sequences of the synthetic peptides that using in HIV-1 SSEIA 3.4 The example of locations in the microplate 3.5 The example of comparing results of HIV-1 V3 serotype and gag-pol genotype 4.1 The results of HIV-1 V3 serotype in each study population that separated by year of sample collection 4.2 The results of HIV-1 V3 serotype in the available samples of all study populations 4.3 The details of samples that showed indeterminate serotype 4.4 The results of HIV-1 gag-pol genotype among the first and second study populations during 2009-2012 4.5 The results of HIV-1 gag-pol genotype in the first and second study populations, categorized by year of sample collection 4.6 The results of evaluation of HIV-1 V3 serotype and gag-pol genotype in each study population and year of sample collection 4.7 The results of evaluation of HIV-1 V3 serotype and gag-pol genotype in each study population and year of sample collection 4.8 The results of evaluation of HIV-1 V3 serotype and gag-pol genotype that classified subtype 4.8 The results of gag-pol genotype, V3 serotype and env C2V3C3 genotype in 73 discordant results 4.9 The details of patients who infected with HIV-1 subtype C,

LIST OF TABLES

Table 4.10	Subtype characterizations of gag-pol and env C2V3C3	67
	sequences in the patients who infected with HIV-1	
	subtype C, G and inter-subtype recombinants	
Table 4.11	The conclusion results of HIV-1 subtype in each study	74
	population NNERSITION NNERSITION NATIONIVERSITION	
ິລິ	้ขสิทธิ์มหาวิทยาลัยเชียงใหม่	
C A	Copyright [©] by Chiang Mai University	

LIST OF FIGURES

Figure	2.1	The structure of a mature HIV-1 particle	6
Figure	2.2	Illustrates the HIV-1 genome	8
Figure	2.3	Demonstrates the HIV-1 life cycle in the host cell.	10
Figure	2.4	Phylogenetic relationships of HIV groups M, N, O, CRFs,	12
		and the distance between HIV-1 and HIV-2	
Figure	2.5	The generation of HIV recombinant	15
Figure	2.6	The percentage of people living with HIV by country in ASIA and the Pacific	22
Figure	2.7	The global distribution and prevalence of HIV-1 subtypes and recombinant forms	24
Figure	3.1	The regions of Thailand were based on the Bureau of policy and strategy, Ministry of Public Health.	30
Figure	3.2	Diagram represents the amplification and sequencing strategies of the ViroSeq HIV-1 genotyping assay version 2.0	32
Figure	3.3	Diagram displays the amplification and sequencing strategies of the TRUGENE® HIV-1 Genotyping Assay.	33
Figure	3.4	The diagram presents the research design of this study.	35
Figure	4.1	The distribution of HIV-1 V3 serotypes in all study populations.	46
Figure	4.2	The distribution of HIV-1 <i>gag-pol</i> genotypes among the first and second study populations during 2009-2012	50
Figure	4.3	The subtype characterizations of <i>gag-pol</i> sequences from	53
		HIV-1 inter-subtype recombination	
Figure	4.4	The three genomes of HIV-1 inter-subtype recombinant with	57
		CRF01_AE in gag-pol region and subtype B in env C2V3C3 region	

LIST OF FIGURES

Figure	4.5	The four genomes of HIV-1 inter-subtype recombinant with	58
		subtype B in gag-pol region and CRF01_AE in env C2V3C3 region	
Figure	4.6	The genomes of HIV-1 subtype C and C recombinant with	61
		subtype CRF01_AE	
Figure	4.7	The genome of HIV-1 subtype G	62
Figure 4.8		The eight genomes of HIV-1 infected patients who had	63
		subtype characterizations of <i>gag-pol</i> sequences as B/CRF01_AE	
Figure	4.9	The five genomes of HIV-1 infected patients that subtype	64
		characterizations of gag-pol sequences show CRF01_AE/B	
Figure	4.10	The genomes of two samples of HIV-1 infected patients with	65
		subtype characterizations of gag-pol sequences show	
		CRF01_AE/B/AE recombination	
Figure	4.11	The genome of HIV-1 inter-subtype recombination which	65
		subtype characterizations of gag-pol sequences show	
		B/CRF01_AE/B and env C2-V3-C3 genotype as CRF01_AE	
Figure	4.12	The genome of HIV-1 inter-subtype recombination which	66
	ຄິ	subtype characterizations of <i>gag-pol</i> sequences show B/C recombination	
Figure	4.13	Neighbor-joining tree of the HIV-1 pol nucleotide sequences	72
	А	from the inter-subtype recombinants, subtype C, subtype G	
		and indeterminate serotypes by SSEIA.	
Figure	4.14	Neighbor-joining tree of the HIV-1 env nucleotide sequences	73
		from the inter-subtype recombination, subtype C and G.	

LIST OF ABBREVIATIONS

μg	microgram
μL	microliter
μΜ	micromolar
AEC	Asean Economic Community
AEM	The Asian Epidemic Model Projections
AFTA	ASEAN Free Trade Area
AIDS	Acquired immune deficiency syndrome
APOBEC	Apolipoprotein B mRNA editing enzyme, catalytic
8.	polypeptide
ART	Antiretroviral therapy
ARV	AIDS-associated retrovirus
ARV	Antiretroviral
bp	base pair
C	Constant region
CA	Capsid protein
CCR5	CC-chemokine receptor 5
CD M	Cluster of differentiation
CDC	Centers for Disease Control and Prevention
cDNA	Complementary DNA
CRFs	Circulating recombinant forms
CXCR4	CXC-chemokine receptor 4
DNA	Deoxyribonucleic acid
dsDNA	double-stranded DNA
ELISA	Enzyme-linked immunosorbent assay
env	Envelope
FCS	Fetal Calf Serum
FI	Fusion inhibitor
gag	group specific antigens
gp	Glycoprotein

LIST OF ABBREVIATIONS

H ₂ O ₂ -OPD	Hydrogen peroxide-o-phenylenediamine
HIV	Human immunodeficiency virus
HTLV-III	Human T-lymphotropic virus type III
IAs	HIV immunoassays
IDUs	Intravenous drug users
IN	Integrase
INIs	Integrase inhibitors
IR	intersubtype recombinant
kb	kilo base pair
LAV	Lymphadenopathy-associated virus
LTR	Long terminal repeat
M 335 6	Major
MA	Matrix protein
mL	Milliliter
mRNA	messenger Ribonucleic acid
MSM	Men who have sex with men
N	New, or non-M, non-O
NAP	National AIDS Program
NC	Nucleocapsid protein
NHSO	National Health Security Office of Thailand
NNRTIs ight ^C b	Non-nucleoside reverse transcriptase inhibitors
NIH	National Institutes of Health
nm	Nanometer
NRTIs	Nucleoside reverse transcriptase inhibitors
0	Outlier
OD	optical density
PBS	Phosphate-buffered saline
PCP	Pneumocystis carinii pneumonia
PCR	Polymerase chain reaction

LIST OF ABBREVIATIONS

PEIA	V3-loop peptide enzyme immunoassay
pg	picogram
PIC	pre-integration complex
PIs	Protease inhibitors
PR	Proteases enzyme
RNA	Ribonucleic acid
RNase H	Ribonuclease H
RRE	rev response element
RT	Reverse transcriptase
SIV	Simian immunodeficiency virus
SSEIA	subtype-specific enzyme immunoassay
ssRNA	single-stranded RNA
SU	Surface glycoprotein
TAE	Tris-acetate-EDTA
TAR	transcriptional activation region
TM	Transmembrane glycoprotein
URF	Uniqe recombinant form
V	Variable region
who adans un	World Health Organization
Copyright [©]	by Chiang Mai University
All rig	hts reserved